Seventure backs MaaT

Seventure is the first investor in MaaT, and has committed to investing a further €1m in the company depending on the achievement of scientific milestones.

The technology transfer office of the French National Institute for Agricultural Research has also become a shareholder in MaaT following the transaction.

Company
Seventure helped launch MaaT in August 2013 with its co-founders Pierre Belichard, Hervé Affagard, Joël Doré and Pierre Rimbaud.

MaaT is developing a microbiotherapy treatment for hospital use. It is designed to treat patients who are suffering from treatment-induced microbial imbalance, also known as dysbiotic enteropathies.

The microbiotherapeutic treatment is designed to reduce or eliminate gastrointestinal side-effects.

People
Hervé Affagard is the CEO of MaaT. Isabelle de Cremoux is CEO and managing partner of Seventure.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Seventure (SPEF)
• France